Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 5 Science Park NEW HAVEN CT 06511-1966 |
Tel: | N/A |
Website: | https://www.arvinas.com |
IR: | See website |
Key People | ||
John G. Houston Chairman of the Board, President, Chief Executive Officer | Randy Teel Interim Chief Financial Officer, Treasurer | Ian Taylor Chief Scientific Officer |
Jared Morris Freedberg General Counsel | Noah Berkowitz Chief Medical Officer |
Business Overview |
Arvinas, Inc. is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The Company uses its PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It has four investigational clinical-stage programs: vepdegestrant (ARV-471) for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-766 and bavdegalutamide for the treatment of men with metastatic castration-resistant prostate cancer, and ARV-102 for the treatment of patients with neurodegenerative disorders. Its product candidate, ARV-393, is designed to target the B-cell lymphoma 6, or BCL6 protein. |
Financial Overview |
For the fiscal year ended 31 December 2023, Arvinas Inc revenues decreased 40% to $78.5M. Net loss increased 30% to $367.3M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development increase of 21% to $379.7M (expense), General and administrative increase of 26% to $100.3M (expense). |
Employees: | 445 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $1,124M as of Dec 31, 2023 |
Annual revenue (TTM): | $78.50M as of Dec 31, 2023 |
EBITDA (TTM): | -$396.70M as of Dec 31, 2023 |
Net annual income (TTM): | -$367.30M as of Dec 31, 2023 |
Free cash flow (TTM): | -$350.70M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 68,308,405 as of Mar 31, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |